Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient

Autor:	Pier Luigi Zinzani, Stefano Pileri, Alessandro Broccoli, Monica Celli, Claudio Agostinelli, Cinzia Pellegrini, Lisa Argnani
Přispěvatelé:	Broccoli A, Pellegrini C, Celli M, Argnani L, Agostinelli C, Pileri S, Zinzani PL
Rok vydání:	2014
Předmět:	Cancer Research Angioimmunoblastic T-cell lymphoma Angiogenesis Inhibitors Antineoplastic Agents Lymphoma T-Cell Transplantation Autologous chemistry.chemical_compound Recurrence Antineoplastic Combined Chemotherapy Protocols Humans Medicine Single agent Neoplasm Metastasis Cyclophosphamide Lenalidomide Complete response Refractory Angioimmunoblastic T-cell Lymphoma Neoplasm Staging business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Thalidomide Vascular endothelial growth factor Treatment Outcome T-Cell Lymphoma Project Oncology chemistry Doxorubicin Vincristine Immunoblastic Lymphadenopathy Positron-Emission Tomography Retreatment Cancer research Prednisone Female Lymph Nodes Tomography X-Ray Computed business medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 14:e119-e122
ISSN:	2152-2650
DOI:	10.1016/j.clml.2014.01.011
Popis:	No abstract available.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca39cdec98026752f7f569288f9e79f0 https://doi.org/10.1016/j.clml.2014.01.011 Zobrazit plný text záznamu Full Text from ScienceDirect